Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies.

Abstract

PURPOSE OF REVIEW:

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide.

RECENT FINDINGS:

With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA. Monoclonal antibodies such as omalizumab, rituximab, and mepolizumab are among these new options. This review summarizes the pathogenesis and clinical manifestations of EGPA and critically examines current and emerging therapies.

• Authors: Erika P Navarro-Mendoza, Gabriel J Tobón
• Journal: Current rheumatology reports (Curr Rheumatol Rep) Vol. 20 Issue 5 Pg. 23 (04 02 2018) ISSN: 1534-6307 [Electronic] United States
• PMID: 29611001 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Glucocorticoids
• Immunosuppressive Agents
• Omalizumab
• Rituximab
• Cyclophosphamide
• mepolizumab
• Azathioprine

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Azathioprine (therapeutic use)
• Churg-Strauss Syndrome (diagnosis, drug therapy, etiology)
• Cyclophosphamide (therapeutic use)
• Glucocorticoids (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Omalizumab (therapeutic use)
• Rituximab (therapeutic use)